The examination of effects of switching to GLP-1 analog liraglutide or adding on insulin glargine once daily for type 2 diabetes controlled insufficiently by DPP-4 inhibitors and other oral anti-diabetic agents combination (multicenter study).

Trial Profile

The examination of effects of switching to GLP-1 analog liraglutide or adding on insulin glargine once daily for type 2 diabetes controlled insufficiently by DPP-4 inhibitors and other oral anti-diabetic agents combination (multicenter study).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BOOST-G
  • Most Recent Events

    • 20 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to University Hospital Medical Information Network - Japan record.
    • 03 Jun 2015 Planned number of patients changed from 100 to 60, according to University Hospital Medical Information Network - Japan record.
    • 13 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top